首页> Clinical genitourinary cancer> Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer With UGN-102: Outcomes From the 5-Year Long-Term Extension Study of the Single-Arm, Phase 2b Optima II Study.

Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer With UGN-102: Outcomes From the 5-Year Long-Term Extension Study of the Single-Arm, Phase 2b Optima II Study.

导出 LinkOut

翻译打印收藏纠错

第一作者： Neal D,Shore

第一单位： START Carolinas Research, AUC Urology Specialists, Myrtle Beach, SC. Electronic address: nshore@auclinics.com.

作者： Neal D,Shore ^[1] ; K Kent,Chevli ^[2] ; Daniel,Saltzstein ^[3] ; Yaron,Ehrlich ^[4] ; Jay D,Raman ^[5] ; Boris,Friedman ^[6] ; Alexander,Sankin ^[7] ; Douglas,Scherr ^[8] ; William C,Huang ^[9] ; Michael J,Louie ^[10] ; Sunil,Raju ^[10] ; Brent,Burger ^[10] ; Andrew,Meads ^[10] ; Mark,Schoenberg ^[11] ; OPTIMA II Study

作者单位： START Carolinas Research, AUC Urology Specialists, Myrtle Beach, SC. Electronic address: nshore@auclinics.com. ^[1] Jacobs School of Medicine and Biomedical Sciences, University of Buffalo (State University of New York), Buffalo, NY. ^[2] Division of Urology, Urology San Antonio, San Antonio, TX. ^[3] Urology Unit, Rabin Medical Center, Petah-Tikva, Israel. ^[4] Department of Urology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA. ^[5] Lady Davis Carmel Medical Center, Technion - Israel Institute of Technology, Haifa, Israel. ^[6] Department of Urology, Albert Einstein College of Medicine, Bronx, NY. ^[7] Department of Urology, Weill Cornell Medical College of Cornell University, New York, NY. ^[8] Department of Urology, NYU Grossman School of Medicine, New York, NY. ^[9] UroGen Pharma, Princeton, NJ. ^[10] Department of Urology, Albert Einstein College of Medicine, Bronx, NY; UroGen Pharma, Princeton, NJ. ^[11]

关键词 Chemoablation Mitomycin NMIBC Patient care TURBT